A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin

Purpose

The purpose of this study is to see how well LY3938577 works and how safe it is compared to degludec in people with type 2 diabetes. Participation in the study will last about 26 weeks.

Condition

  • Diabetes Mellitus, Type 2

Eligibility

Eligible Ages
Between 18 Years and 70 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Have type 2 diabetes - Are receiving ≥20 units of basal insulin per day and ≤55 units/day and ≤1.5 units/kg/day at screening - Have hemoglobin A1c (HbA1c) 7.5% to 10.5% inclusive - Have a body mass index (BMI) of 20 or higher and less than 35 kilograms per square meter (kg/m2)

Exclusion Criteria

  • Have type 1 diabetes

Study Design

Phase
Phase 2
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
LY3938577 		Participants will receive LY3938577 subcutaneously (SC)
  • Drug: LY3938577
    Administered SC
Active Comparator
Degludec 		Participants will receive degludec SC
  • Drug: Degludec
    Administered SC

Recruiting Locations

Tucson Clinical Research Institute
Tucson 5318313, Arizona 5551752 85712

Encompass Clinical Research
Spring Valley 5398277, California 5332921 91978
Contact:
619-660-9068

University Clinical Investigators, Inc.
Tustin 5404119, California 5332921 92780
Contact:
714-734-7944

Tampa Bay Medical Research
Clearwater 4151316, Florida 4155751 33761
Contact:
727-724-3316

Encore Medical Research
Hollywood 4158928, Florida 4155751 33024
Contact:
954-400-1725

Clinical Research of Central Florida
Lakeland 4161438, Florida 4155751 33805
Contact:
863-853-5400

Encore Medical Research - Weston
Weston 4178003, Florida 4155751 33331
Contact:
954-777-8827

Iowa Diabetes and Endocrinology Research Center
West Des Moines 4881346, Iowa 4862182 50266

Washington University School of Medicine
St Louis 4407066, Missouri 4398678 63110
Contact:
314-712-1765

Accellacare - Wilmington
Wilmington 4499379, North Carolina 4482348 28401
Contact:
910-815-6108

AMR Clinical
Norman 4543762, Oklahoma 4544379 73069
Contact:
405-701-8999

Tribe Clinical Research, LLC
Greenville 4580543, South Carolina 4597040 29607
Contact:
864-334-0141

Holston Medical Group
Bristol 4608657, Tennessee 4662168 37620
Contact:
423-990-2478

Texas Diabetes & Endocrinology, P.A.
Austin 4671654, Texas 4736286 78749
Contact:
512-334-3505

Velocity Clinical Research, Dallas
Dallas 4684888, Texas 4736286 75230

Juno Research
Houston 4699066, Texas 4736286 77040
Contact:
713-779-5494

Southern Endocrinology Associates
Mesquite 4710826, Texas 4736286 75149
Contact:
214-693-0904

Consano Clinical Research, LLC
Shavano Park 4728147, Texas 4736286 78231
Contact:
210-545-4900

Texas Valley Clinical Research
Weslaco 4740629, Texas 4736286 78596
Contact:
956-431-8090

Chrysalis Clinical Research
St. George 5546220, Utah 5549030 84790
Contact:
435-656-1704

More Details

Status
Recruiting
Sponsor
Eli Lilly and Company

Study Contact

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
317-615-4559
LillyTrials@Lilly.com